Viridian Therapeutics Inc (NASDAQ:VRDN) price on Thursday, March 28, remained unchanged to $17.51.
A look at the stock’s price movement, the close in the last trading session was $17.51. Turning to its 52-week performance, $30.30 and $10.93 were the 52-week high and 52-week low respectively. Overall, VRDN moved -13.19% over the past month.
Viridian Therapeutics Inc’s market cap currently stands at around $1.10 billion. Analysts project the company’s earnings per share (EPS) to be -$1.1, which has seen fiscal year 2024 EPS growth forecast to increase to -$4.54 and about -$4.57 for fiscal year 2025. Per the data, EPS growth is expected to be 14.50% for 2024 and -0.70% for the next financial year.
The average forecast suggests down to a -36.40% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2024 to grow to $270k, representing a -14.00% decline on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that VRDN is a 100% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
VRDN’s current price about -3.83% and -6.91% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 44.87, while 7-day volatility ratio is 4.99% and 6.41% in the 30-day chart. Further, Viridian Therapeutics Inc (VRDN) has a beta value of 1.10, and an average true range (ATR) of 1.11.
If we refocus on Viridian Therapeutics Inc (NASDAQ:VRDN), historical trading data shows that trading volumes averaged 1.31 million over the past 10 days and 981.51K over the past 3 months. The company’s latest data on shares outstanding shows there are 62.77 million shares.
The 11.02% of Viridian Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 90.43% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 7.62 million on Mar 15, 2024, giving us a short ratio of 7.46. The data shows that as of Mar 15, 2024 short interest in Viridian Therapeutics Inc (VRDN) stood at 12.14% of shares outstanding, with shares short falling to 7.75 million registered in Feb 15, 2024. Current price change has pushed the stock -19.61% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VRDN stock continues to rise going into the next quarter.
